Volume 2.34 | Aug 28

Cancer Stem Cell News 2.34 August 28, 2013
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter
 
TOP STORY
Activation of MAPK Pathways Due to DUSP4 Loss Promotes Cancer Stem Cell-Like Phenotypes in Basal-Like Breast Cancer
Scientists investigated how DUSP4 regulates the MEK and JNK pathways in modifying cancer stem cell (CSC)-like behavior. DUSP4 loss increased mammosphere formation and the expression of the CSC-promoting cytokines IL-6 and IL-8. [Cancer Res] Abstract
Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more
 
PUBLICATIONS (Ranked by impact factor of the journal)
The Noninflammatory Role of High Mobility Group Box 1/Toll-Like Receptor 2 Axis in the Self-Renewal of Mammary Cancer Stem Cells
Through the transcription profiling of the murine ErbB2+ tumor cell line TUBO vs. derived cancer stem cell (CSC)-enriched mammospheres, Toll-like receptor 2 was identified as two-fold overexpressed in CSCs, as confirmed by qPCR and cytofluorimetric analysis. [FASEB J] Abstract

Nuclear Reprogramming of Luminal-Like Breast Cancer Cells Generates Sox2-Overexpressing Cancer Stem-Like Cellular States Harboring Transcriptional Activation of the mTOR Pathway
Researchers used Yamanaka’s stem cell technology in an attempt to create stable cancer stem cell (CSC) research lines in which to dissect the transcriptional control of mTOR – the master switch of cellular catabolism and anabolism – in CSC-like states. [Cell Cycle] Full Article

Ovarian Cancer Stem Cells Are Enriched in Side Population and Aldehyde Dehydrogenase Bright Overlapping Population
Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) of ovarian cancer have been isolated by side population (SP) analysis, ALDEFLUOR assay and using cell surface markers. However, these approaches are not definitive markers for CSCs/CICs, and it is necessary to refine recent methods for identifying more highly purified CSCs/CICs. Investigators analyzed SP cells and aldehyde dehydrogenese bright cells from ovarian cancer cells. [PLoS One] Full Article

DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 3, X-Linked Is an Immunogenic Target of Cancer Stem Cells
The authors previously reported that vaccination with CD133+ murine melanoma cells exhibiting biological cancer stem cell (CSC) features induced CSC-specific effector T cells. These were capable of eradicating CD133+ tumor cells in vivo, thereby curing the parental tumor. They indicate that DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic protein preferentially expressed in CD133+ tumor cells. [Cancer Immunol Immunother] Abstract

Brefeldin A Effectively Inhibits Cancer Stem Cell-Like Properties and MMP-9 Activity in Human Colorectal Cancer Colo 205 Cells
Brefeldin A (BFA) is an antibiotic that is known to block protein transport and induce endoplasmic reticulum stress in eukaryotic cells, but its effects on colorectal cancer stem cells are unknown. Researchers investigated the inhibitory effect of BFA on human colorectal cancer Colo 205 cells. [Molecules]
Abstract | Full Article

8-Bromo-5-Hydroxy-7-Methoxychrysin Targeting for Inhibition of the Properties of Liver Cancer Stem Cells by Modulation of Twist Signaling
Investigators isolated and characterized a small population of CD133+ cells that existed in the human hepatocellular carcinoma (HCC) cell line SMMC-7721 by MACS and investigated the possible roles of 8-bromo-7-methoxychrysin, a synthetic analogue of chrysin, in inhibiting the properties of CD133+ sphere-forming cells derived from the HCC cell line SMMC-7721, namely liver cancer stem cells. [Int J Oncol] Abstract

Ribophorin II Regulates Breast Tumor Initiation and Metastasis through the Functional Suppression of GSK3β
Scientists showed that ribophorin II (RPN2) regulates cancer stem cell properties through the stabilization of mtp53 (R280K and del126-133) in breast cancer. RPN2 stabilized mtp53 by inactivation of glycogen synthase kinase-3β (GSK3β) which suppresses Snail, a master regulator of epithelial to mesenchymal transition. [Sci Rep] Full Article

Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications
 
REVIEWS
Deadly Crosstalk: Notch Signaling at the Intersection of EMT and Cancer Stem Cells
Notch signaling is an evolutionarily conserved pathway involved in cell fate control during development, stem cell self-renewal and postnatal tissue differentiation. Roles for Notch in carcinogenesis, in the biology of cancer stem cells, tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) have been reported. The authors describe how accumulated evidence suggests that Notch inhibition is an attractive strategy for the treatment of several cancers, at least in part because of its potential to reverse or prevent EMT. [Cancer Lett] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
OncoMed Pharmaceuticals Granted Patent for Methods of Treating Cancer with Its Novel Wnt Pathway Targeting Antibody Vantictumab
OncoMed Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,507,442 to OncoMed for methods of treating cancer with its antibody vantictumab. Vantictumab targets and inhibits the Wnt pathway, which is believed to be an important cancer stem cell pathway. [GlobeNewswire, Inc.] Press Release

Mayo Clinic to Open Stem Cell Laboratory in Phoenix
Mayo Clinic in Arizona will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Children’s Hospital. [Mayo Foundation for Medical Education and Research] Press Release

Enter Our Contest  
Cancer Stem Cell News is giving away a free registration for the World Stem Cell Summit 2013 in San Diego! Click here to enter “Your Window to the World of Regenerative Medicine”.

 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
 
EVENTS
NEW 20th International Society for Cellular Therapy (ISCT) Annual Meeting 2014
April 23-26, 2014
Paris, France

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Principal Scientist – Cancer Stem Cells (Pharma Professionals Europe Ltd)

Postdoctoral Fellowships – Cancer Stem Cell Biology and Pharmacogenomics (Biotech Research & Innovation Center, University of Copenhagen)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Stem Cell and Cancer Biology (University of Pennsylvania)

Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Appointee – Cell Cycle Regulation in Tumor Stem Cells (Rutgers University, Rutgers Cancer Institute of New Jersey)

Research Technician – Self-Renewal of Cancer Stem Cells (University of Chicago)

Postdoctoral Researcher – Molecular Bases of Cancer Initiation and Progression (New York University School of Medicine)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us